P1/2, N=7, Terminated, Rubius Therapeutics | RTX-224 was well-tolerated with no DLTs, no related deaths, SAEs or Gr. 3/4 AEs and cleared rapidly (w/in 10 min).

2 years ago

Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases

PD-L1 (Programmed death ligand 1)

RTX-224

2years

RTX-224-01: RTX-224 Monotherapy in Patients With Solid Tumors (clinicaltrials.gov)

P1/2, N=128, Active, not recruiting, Rubius Therapeutics | Recruiting --> Active, not recruiting

2 years ago

Enrollment closed • Metastases

PD-L1 (Programmed death ligand 1)

RTX-224

over2years

A phase 1/2 study of RTX-224, an engineered red blood cell expressing 4-1BB ligand and membrane-bound IL-12, for the treatment of patients with select advanced solid tumors. (ASCO 2022)

Multiple technologies will be employed to profile the innate and adaptive responses following RTX-224 treatment. The study is open and enrolling patients in Phase 1.

over 2 years ago

Clinical • P1/2 data • IO biomarker

CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)

RTX-224

almost3years

RTX-224 Monotherapy in Patients With Solid Tumors (clinicaltrials.gov)

P1/2, N=128, Recruiting, Rubius Therapeutics

almost 3 years ago

New P1/2 trial

PD-L1 (Programmed death ligand 1)

RTX-224

3years

RTX-224, An Engineered Allogeneic Red Cell Therapeutic Expressing 4-1BBL and IL-12, Activates Immune Cells in Blood and Spleen to Promote Tumor Growth Inhibition in Mice (SITC 2021)

These results align with published data suggesting that activated T cells in the spleen or blood can replenish exhausted tumor-infiltrating cells. Conclusions Taken together, these data unveil the mechanism of action of mRBC-224 and suggest that mRBC-224 activate immune cells in the spleen and blood, leading to their trafficking into the tumor microenvironment to promote efficacy.

3 years ago

Preclinical

CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • GZMB (Granzyme B)

RTX-224